



(1) Publication number:

0 489 404 A3

EUROPEAN PATENT APPLICATION

(21) Application number: 91120768.6

2 Date of filing: 03.12.91

(51) Int. CI.⁵: **A61K 31/00**, A61K 31/35, A61K 31/40, A61K 31/415

- 30 Priority: 05.12.90 US 622679
- Date of publication of application:10.06.92 Bulletin 92/24
- Designated Contracting States:
 AT BE CH DE DK ES FR GB GR IT LI LU NL SE
- Bate of deferred publication of the search report: 14.10.92 Bulletin 92/42
- Applicant: E.R. SOUIBB & SONS, INC. P.O.Box 4000 Princeton New Jersey 08543-4000(US)
- Inventor: Grover, Gary J. 101 Bowne Station Road Stockton, NJ 08559(US)
- Representative: Josif, Albert et al Baaderstrasse 3
 W-8000 München 5(DE)
- 64 Method of treating shock using a potassium channel activator.
- © A novel method for reducing or preventing impairment of cardiac and peripheral function resulting from shock is disclosed. The method comprises administering to a patient in need thereof a potassium channel activator.



PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

EP 91 12 0768

	DOCUMENTS CONSII	DERED TO BE	RELEVANT		
Category	Citation of document with in of relevant pas	dication, where approp		Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
Х	DRUG DEVELOPMENT RES 1, 1990, pages 91-97 T. HAMAGUCHI et al.: effects of nicorand paradox-induced inju * Paragraph: "Discus	7, Wiley-Liss, : "Cardioprote il on calcium ury"	, Ínc.;	1,2,3	A 61 K 31/00 A 61 K 31/35 A 61 K 31/40 A 61 K 31/415
х	EP-A-0 351 767 (SQU * Entire document *	JIBB)		1,2,3,4	
Х	RESPIRATION AND CIRC no. 11, November 198 J. HAYASHI et al.: ' of nicorandil again induced myocardial o hypoxia" * Page 1235, abstrac	39, pages 123: "Protective e st catecholam damage under	1-1235; ffects	1,2,3,4	
P,X	EP-A-0 401 010 (SQI * Claims; page 11 *	UIBB) -/	_	1-6	TECHNICAL FIELDS SEARCHED (Int. Cl.5)
The Sear the proviout a me Claims s Claims s Claims n Reason f	omplete SEARCH The Division considers that the present sions of the European Patent Convention aningful search into the state of the arearched completely: earched incompletely: earched incompletely: or the limitation of the search: t is not clear what tration is meant compound cannot y its pharmacolog				
	Place of search	Date of comp 15-07-	letion of the search	KIA	Examiner VER T.
CATEGORY OF CITED DOCUMENTS X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background		C: theory or principle underlying the invention C: earlier patent document, but published on, or after the filing date O: document cited in the application L: document cited for other reasons C: member of the same patent family, corresponding document		e invention lished on, or n	



	CL	AIMS INCURRING FEES
The	presen	t European patent application comprised at the time of filing more than ten claims.
[All claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for all claims.
		Only part of the claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid.
		namely claims:
		No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.
	LA	CK OF UNITY OF INVENTION
inve	ntion a	n Division considers that the present European patent application does not comply with the requirement of unity of and relates to several inventions or groups of inventions,
nam	ely:	
	see	sheet -B-
	x	All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
		Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid,
		namely claims:
		None of the further search fees has been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims,
1		namely claims:



EPO FORM 1503 03.82 (P0410)

PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 91 12 0768

	DOCUMENTS CONSIDERED TO BE RELEVAN	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)	
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
A	TRENDS IN PHARMACOLOGICAL SCIENCE, vol. 9, January 1988, pages 21-28, Elsevier Publications, Cambridge, GB; N.S. COOK: "The pharmacology of potassium channels and their therapeutic potential"		
A	CIRCULATIONS RESEARCH, vol. 62, no. 4, April 1988, pages 679-686; R.P. HOF et al.: "Mechanism of action and systemic and regional hemodynamics of the potassium channel activator BRL34915 and its enantiomers"		
A	AMERICAN JOURNAL OF PHYSIOLOGY, vol. 259, no. 2, part 2, August 1990, pages F348-F356, The American Physiological Society; L. DUBE et al.: "Hypotonic shock activated a maxi K+ channel in primary cultured proximal tubule cells"		TECHNICAL FIELDS SEARCHED (Int. Cl.5)
Α	EP-A-0 389 861 (FUJISAWA)		
Α	EP-A-0 359 537 (BEECHAM)		
A	EP-A-0 344 747 (FUJISAWA)		



LACK OF UNITY OF INVENTION a posteriori

The Search Division considers that the present European patent application does not comply with the requirement of unity of invention and relates to several inventions or groups of inventions, namely:

- 1. claims 1,2,3 in part,4: Use of nicorandil against the impairment of cardiac function due to shock.
- 2. claim 3 in part: Use of minoxidil against the impairment of cardiac function due to shock.
- 3. claim 3 in part: Use of pinacidil against the impairment of cardiac function due to shock.
- 4. claim 3 in part: Use of cromakalim against the impairment of cardiac function due to shock.
- 5. claims 3,5,in part,6: Use of a compound of formula C,E or F against the impairment of cardiac function due to shock.
- 6. claims 3,5 in part: Use of a compound of formula D, against the impairment of cardiac function due to shock.